These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 34695229)

  • 21. Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis.
    Sharifi Aliabadi L; Azari M; Taherian MR; Barkhordar M; Abbas SAM; Azari M; Ahmadvand M; Salehi Z; Rouzbahani S; Vaezi M
    Virol J; 2024 May; 21(1):103. PubMed ID: 38702752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
    Piñana JL; Rodríguez-Belenguer P; Caballero D; Martino R; Lopez-Corral L; Terol MJ; Vazquez L; Calabuig M; Sanz-Linares G; Marin-Jimenez F; Alonso C; Montoro J; Ferrer E; Facal A; Pascual MJ; Rodriguez-Fernandez A; Olave MT; Cascales-Hernandez A; Gago B; Hernández-Rivas JÁ; Villalon L; Corona M; Roldán-Pérez A; Ribes-Amoros J; González-Santillana C; Garcia-Sanz R; Navarro D; Serrano-López AJ; Cedillo Á; Soria-Olivas E; Sureda A; Solano C;
    Ann Hematol; 2022 Sep; 101(9):2053-2067. PubMed ID: 35780254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is a third SARS-CoV-2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?
    Spyridonidis A
    Br J Haematol; 2023 Apr; 201(1):9-10. PubMed ID: 36477621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation.
    Bankova AK; Pasin C; Huang A; Cicin-Sain C; Epp S; Audige A; Mueller NJ; Nilsson J; Vilinovszki O; Nair G; Wolfensberger N; Hockl P; Schanz U; Trkola A; Kouyos R; Hasse B; Zinkernagel AS; Manz MG; Abela IA; Müller AMS
    Br J Haematol; 2023 Apr; 201(1):58-63. PubMed ID: 36382698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.
    Infante MS; Nemirovsky D; Devlin S; DeWolf S; Tamari R; Dahi PB; Lee YJ; Chung DJ; Politikos I; Barker J; Giralt SA; Babady NE; Ramanathan L; Papanicolaou GA; Seo S; Kamboj M; Perales MA; Shah GL
    Transplant Cell Ther; 2024 Jan; 30(1):116.e1-116.e12. PubMed ID: 37806446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation.
    Sherman AC; Cheng CA; Swank Z; Zhou G; Li X; Issa NC; Walt DR; Baden LR; Soiffer RJ
    Transplant Cell Ther; 2023 May; 29(5):337.e1-337.e5. PubMed ID: 36736784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study.
    Ngo D; Chen J; Tinajero J; Aribi A; Arslan S; Marcucci G; Nakamura R; Al Malki MM; Forman SJ; Dadwal S; Ali H
    Stem Cell Res Ther; 2023 Apr; 14(1):95. PubMed ID: 37072867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the antibody response to SARS-COV-2 vaccination amongst kidney transplant recipients at a single nephrology centre.
    Chukwu CA; Mahmood K; Elmakki S; Gorton J; Kalra PA; Poulikakos D; Middleton R
    PLoS One; 2022; 17(3):e0265130. PubMed ID: 35271655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of mRNA1273 SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Single center experience.
    Huguet M; Boigues M; Sorigué M; Blanco J; Quirant B; Ferrà C; ;
    Med Clin (Barc); 2024 Apr; 162(7):313-320. PubMed ID: 38000941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
    Wu X; Wang L; Shen L; He L; Tang K
    J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study.
    Rozen-Zvi B; Yahav D; Agur T; Zingerman B; Ben-Zvi H; Atamna A; Tau N; Mashraki T; Nesher E; Rahamimov R
    Clin Microbiol Infect; 2021 Aug; 27(8):1173.e1-1173.e4. PubMed ID: 33957273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
    Mori Y; Uchida N; Wake A; Miyawaki K; Eto T; Nakamura T; Iwasaki H; Ito Y; Tanimoto K; Katayama Y; Imamura Y; Takahashi T; Fujisaki T; Kamimura T; Choi I; Ishitsuka K; Yoshimoto G; Ogawa R; Sugita J; Takamatsu Y; Tanimoto K; Hidaka T; Miyamoto T; Akashi K; Nagafuji K
    Vaccine; 2023 Nov; 41(47):6899-6903. PubMed ID: 37866994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders.
    Piñana JL; López-Corral L; Martino R; Vazquez L; Pérez A; Martin-Martin G; Gago B; Sanz-Linares G; Sanchez-Salinas A; Villalon L; Conesa-Garcia V; Olave MT; Corona M; Marcos-Corrales S; Tormo M; Hernández-Rivas JÁ; Montoro J; Rodriguez-Fernandez A; Risco-Gálvez I; Rodríguez-Belenguer P; Hernandez-Boluda JC; García-Cadenas I; Ruiz-García M; Muñoz-Bellido JL; Solano C; Cedillo Á; Sureda A; Navarro D;
    J Hematol Oncol; 2022 May; 15(1):54. PubMed ID: 35526045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis.
    Meejun T; Srisurapanont K; Manothummetha K; Thongkam A; Mejun N; Chuleerarux N; Sanguankeo A; Phongkhun K; Leksuwankun S; Thanakitcharu J; Lerttiendamrong B; Langsiri N; Torvorapanit P; Worasilchai N; Plongla R; Hirankarn N; Nematollahi S; Permpalung N; Moonla C; Kates OS
    Blood Adv; 2023 Sep; 7(18):5624-5636. PubMed ID: 37389818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients.
    Ali H; Ngo D; Aribi A; Arslan S; Dadwal S; Marcucci G; Nakamura R; Forman SJ; Chen J; Al Malki MM
    Transplant Cell Ther; 2021 Nov; 27(11):938.e1-938.e6. PubMed ID: 34274492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients.
    Clémenceau B; Le Bourgeois A; Guillaume T; Coste-Burel M; Peterlin P; Garnier A; Jullien M; Ollier J; Grain A; Béné MC; Chevallier P
    Cells; 2022 Sep; 11(19):. PubMed ID: 36230971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ursodeoxycholic acid does not reduce SARS-CoV-2 infection in newly allogeneic hematopoietic stem cell transplantation recipients: a prospective NICHE cohort.
    Gao H; Wang J; Zheng X; Pei X; Zheng Y; Zhai W; Zhang R; Chen X; Ma Q; Wei J; Yang D; Pang A; He Y; Feng S; Cao Y; Jiang E
    Front Cell Infect Microbiol; 2024; 14():1324019. PubMed ID: 38505288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
    Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses.
    Ahmed-Belkacem A; Redjoul R; Brillet R; Ahnou N; Leclerc M; López-Molina DS; Soulier A; Gourgeon A; Rodriguez C; Maury S; Pawlotsky JM; Fourati S
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of SARS-CoV-2 Vaccine Doses in Allogeneic Hemopoietic Stem Cell Recipients: A Systematic Review and Meta-Analysis.
    Rubin M; Suelzer E; Ulschmid C; Thapa B; Szabo A; Abid MB
    Asian Pac J Cancer Prev; 2024 Feb; 25(2):393-399. PubMed ID: 38415523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.